eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | thrombocytopenia |
| Comorbidity | C0019196|hepatitis c |
| Sentences | 25 |
| PubMedID- 24714308 | Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection [21]. |
| PubMedID- 20805953 | The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia [111213]. |
| PubMedID- 24304453 | thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment. |
| PubMedID- 21120192 | Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms [28]. |
| PubMedID- 25728497 | Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc). |
| PubMedID- 21188328 | Background and aims: thrombocytopenia in patients with chronic hepatitis c may be the result of several factors: bone marrow inhibition, the decrease of liver thrombopoietin production and an autoimmune mechanism. |
| PubMedID- 24621321 | We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-cc genotype. |
| PubMedID- 24128106 | [eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports]. |
| PubMedID- 25764686 | thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment. |
| PubMedID- 24731162 | Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis. |
| PubMedID- 25209590 | Eltrombopag is a new thrombopoietin receptor agonist which was used successfully in this critical case of thrombocytopenia associated with hepatitis c infection before it became an approved drug for such cases. |
| PubMedID- 20796208 | Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review. |
| PubMedID- 25331767 | Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c. |
| PubMedID- 20731135 | This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy. |
| PubMedID- 26417629 | Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c. |
| PubMedID- 24457056 | We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection. |
| PubMedID- 19689996 | thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation. |
| PubMedID- 20720351 | A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy. |
| PubMedID- 22312391 | However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis. |
| PubMedID- 24653754 | In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy. |
| PubMedID- 20796207 | Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye. |
| PubMedID- PMC4034027 | Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity. |
| PubMedID- 20460556 | Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis. |
| PubMedID- 23001404 | Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response. |
| PubMedID- 25886818 | Eltrombopag received accelerated fda approval in the united states for the treatment of patients with chronic idiopathic thrombocytopenic purpura (itp) in 2008 and full approval in 2011. eltrombopag has been shown to effectively increase platelet counts and reduce thrombocytopenia-associated complications in patients with itp and hepatitis c [14-16]. |
Page: 1